Figure 9.

In vivo anticancer activity study in the disseminated B-cell NHL xenotransplant model. (a) Treatment schedule. B-cell NHL was induced by i.v. tail-vein injection of 2 × 10⁶ Raji-Luc cells at day 0. Lymphoma mice received two direct/pretargeted treatments with α-CD20(DBCO)₁₀ (7.5 mg/kg) and/or PAMAM(D-⁸⁹Y)₈(N)₂₉ (25 mg/kg)/PAMAM(D-⁸⁹Y)₈(N)₂₉ (25 mg/kg, 7.5 mCi/kg) at days 5 and 12. For pretargeted therapies, the dendrimer was administrated 24 h after the administration of α-CD20. Progression of disease was monitored by in vivo bioluminescence imaging on days 0, 5, 11, 19, 25, 32, and 46. Mice were intraperitoneally administrated with 3 mg firefly D-luciferin 15 min prior to each imaging session. Cerenkov bioluminescence imaging studies were performed at days 11 and 19 prior to the administration of firefly D-luciferin to quantify the amount of Y-90-labeled dendrimers accumulated in the body. (b) Time-dependent whole-body bioluminescence intensities of individual lymphoma mice recorded before and after different treatments. The inserts show in vivo bioluminescence images recorded 46 days after the xenotransplantation. (c) Kaplan–Meier paralysis-free survival curves of Raji-Luc xenotransplanted mice after receiving different treatments. (n = 7–8 per group; * denotes p < 0.05; M.S.T. denotes median survival time.)